知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

81 条记录 (耗时 0.031 秒)

    PYRIDOPYRIMIDONE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF
    54.
    发明申请
    PYRIDOPYRIMIDONE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF 失效
    吡咯烷酮衍生物，其制备方法，其治疗方法

    公开(公告)号：US20090048277A1

    公开(公告)日：2009-02-19

    申请号：US12166431

    申请日：2008-07-02

    申请人： Pierre PERREAUT ,  Samir JEGHAM ,  Bernard BOURRIE ,  Pierre CASELLAS ,  Jean-Robert LABROSSE ,  Florence DURAND

    发明人： Pierre PERREAUT ,  Samir JEGHAM ,  Bernard BOURRIE ,  Pierre CASELLAS ,  Jean-Robert LABROSSE ,  Florence DURAND

    IPC分类号： A61K31/519 ,  C07D471/04

    CPC分类号： C07D471/04

    摘要： The disclosure relates to pyrido[2,3-d]pyrimidone compounds, to the preparation thereof and to the therapeutic use thereof, wherein said compounds are of general formula (I): in the form of a base or of an addition salt with an acid which is pharmaceutically acceptable, in the form of hydrates or of solvates, and also in the form of enantiomers, diastereoisomers and a mixture thereof. The disclosure also relates to processes for preparing said compounds, to pharmaceutical compositions containing a compound of general formula (I), and to the therapeutic use of said compounds and compositions.

    摘要翻译： 本公开涉及吡啶并[2,3-d]嘧啶酮化合物，其制备方法及其治疗用途，其中所述化合物为通式（I）：以碱的形式或加成盐与 其为药学上可接受的，为水合物或溶剂化物形式，也为对映异构体，非对映异构体及其混合物的形式。 本公开还涉及制备所述化合物的方法，含有通式（I）化合物的药物组合物以及所述化合物和组合物的治疗用途。

    Aralkyltetrahydropyridines, Their Preparation and Pharmaceutical Compositions Containing Them
    57.
    发明申请
    Aralkyltetrahydropyridines, Their Preparation and Pharmaceutical Compositions Containing Them 失效
    芳烷基四氢吡啶，它们的制备和含有它们的药物组合物

    公开(公告)号：US20080097117A1

    公开(公告)日：2008-04-24

    申请号：US11958476

    申请日：2007-12-18

    申请人： Marco BARONI ,  Bernard BOURRIE ,  Rosanna CARDAMONE ,  Pierre CASELLAS

    发明人： Marco BARONI ,  Bernard BOURRIE ,  Rosanna CARDAMONE ,  Pierre CASELLAS

    IPC分类号： C07C61/29

    CPC分类号： C07D401/04 ,  C07D211/70

    摘要： The present invention relates to compounds of formula (I): in which X represents N or CH; R1 represents a hydrogen or halogen atom or a CF3 group; n is an integer from 1 to 5; A represents a partially saturated carbonaceous bi- or tricycle; it also relates to their salts, solvates, N-oxides, the pharmaceutical compositions containing them, a method for their preparation and synthesis intermediates in this method.

    摘要翻译： 本发明涉及式（I）化合物：其中X表示N或CH; R 1表示氢或卤素原子或CF 3 N 3基团; n为1〜5的整数; A表示部分饱和的碳质二元或三轮车; 它还涉及它们的盐，溶剂合物，N-氧化物，含有它们的药物组合物，其制备方法和该方法中的合成中间体。

    Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination
    60.
    发明授权
    Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination 失效

    公开(公告)号：US06344464B1

    公开(公告)日：2002-02-05

    申请号：US09403507

    申请日：2000-04-18

    申请人： Bernard Bourrie ,  Pierre Casellas ,  Jean-Pierre Maffrand

    发明人： Bernard Bourrie ,  Pierre Casellas ,  Jean-Pierre Maffrand

    IPC分类号： A61K31445

    CPC分类号： A61K31/444 ,  A61K31/4418

    摘要： The invention relates to the use of tetrahydropyridine derivatives of the formula in which: R1 is a halogen or a CF3, (C1-C4)alkyl or (C1-C4)alkoxy group; Y is a nitrogen atom or a CH group; Z′ and Z″ are each hydrogen or a (C1-C3)alkyl group, or one is hydrogen and the other is a hydroxyl group, or the two together are an oxo group; and Z is: a phenyl radical; a phenyl radical monosubstituted by a substituent X, X being: (a) a (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C7)carboxyalkyl, (C1-C4)alkoxycarbonyl(C1-C6)alkyl, (C3-C7)carboxyalkoxy or (C1-C4)alkoxycarbonyl(C1-C6)alkoxy group; (b) a group selected from (C3-C7)cycloalkyl, (C3-C7)cycloalkoxy, (C3-C7)cycloalkylmethyl, (C3-C7)cycloalkylamino and cyclohexenyl, it being possible for said group to be substituted by a halogen, hydroxy, (C1-C4)alkoxy, carboxy, (C1-C4)alkoxycarbonyl, amino or mono- or di-(C1-C4)alkylamino group; or (c) a group selected from phenyl, phenoxy, phenylamino, N—(C1-C3)alkyl-phenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl and styryl, it being possible for said group to be monosubstituted or polysubstituted on the phenyl group by a halogen, CF3, (C1-C4)alkyl, (C1-C4)alkoxy, cyano, amino, mono- or di-(C1-C4)alkylamino, (C1-C4)acylamino, carboxy, (C1-C4)alkoxycarbonyl, aminocarbonyl, mono- or di-(C1-C4)alkylaminocarbonyl, amino(C1-C4)alkyl, hydroxy(C1-C4)alkyl or halogeno(C1-C4)alkyl group; a phenyl radical disubstituted by a substituent R2, R2 being a halogen or a hydroxy, methyl, ethyl, (C3-C6)alkyl, (C1-C4)alkoxy or trifluoromethyl group, and by a substituent X, X being as defined above; a 1-naphthyl or 2-naphthyl radical; or a 1-naphthyl or 2-naphthyl radical substituted in the 5-, 6-, 7- and/or 8-positions by one or two hydroxy groups, one or two (C1-C4)alkoxy groups or a 6,7-methylenedioxy group; or Z″ is hydrogen and Z and Z′ are each independently an unsubstituted or mono-, di- or tri-substituted phenyl group, or a pharmaceutically acceptable salt and solvate thereof, for the preparation of pharmaceutical compositions intended for treating diseases which cause demyelination.